Johnson & Johnson Recalls Invega Syringes
In yet another recall for health care manufacturer Johnson & Johnson, Janseen, a unit of J&J, has voluntarily recalled 70,000 syringes of its antipsychotic drug Invega Sustenna after discovering that some of the pre-filled syringes may have cracks which could possibly affect the drug’s sterility.
Jansen said Friday in a letter that the recall affects lots of 234-milligram-strength injections, but the suspected crack is completely covered by the label and cannot be detected by users. The letter goes on to state that there have been no reports of adverse effects or infection since the product’s launch and no reports of leakage associated with the recalled syringes.
In December 2006, Invega was approved to treat schizophrenia. Thought Janssen said the recall will impact much of the available inventory of its 234-strength drug, the company expects to resume shipping the product in early March and returning to normal levels of availability in April.
Click here to learn more about Baron & Budd’s work with recalled medical devices and unsafe pharmaceuticals.